Amitriptyline effectiveness in burning mouth syndrome: An in‐depth case series analysis
Gerodontology · 2024-12 · 41 (4) · 548-555
DOI: 10.1111/ger.12750 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gerodontology, online erschienen am 21.03.2024. Verfasst von Douglas Rodrigues Gonçalves und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil. Hauptthemen laut MEDLINE: Burning Mouth Syndrome, Amitriptyline. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 68 Literaturangaben. Gefördert von: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
Abstract (Originalsprache)
Objectives
To assess the effectiveness of amitriptyline (AMT), and to identify the determinants of the treatment's effectiveness in patients diagnosed with burning mouth syndrome (BMS).
Background
Treatment of BMS is challenging and no established treatment protocol is available. AMT may be an important treatment option, cout not all patients benefit from this drug. Studies assessing factors related to treatment response are valuable in improving decision‐making. Materials and Methods This case series study examined the medical records of all patients diagnosed with BMS at an oral medicine unit in a university hospital from 2008 to 2022. The patients were divided into responders to AMT and non‐responders to AMT. Data on demographic information, comorbidities, medications, types of symptoms and oral subsites affected were collected. Descriptive and bivariate analyses were conducted to assess the association between the independent variables and the outcome, using the Chi‐squared test ( P < .05).
Results
Three hundred and fourty‐nine patients reported a burning mouth sensation, 50 of them (14.3%) being diagnosed with primary BMS. Of these, 35 were treated with AMT, and 26 (74.2%) responded significantly to AMT. All males responded to AMT, whereas only 67.9% of females responded. The mean dose of AMT among responders was 29.8 ± 12.3 mg, with most patients achieving a response with 25 mg (61.5% of patients), followed by 50 mg (23%). The concomitant use of an anticonvulsant resulted in non‐response.
Conclusions
AMT may be effective in BMS management for most patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Pathology, School of Dentistry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.
- Oral Medicine Unit, Otorhinolaryngology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
- Pain Management and Palliative Medicine Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
- Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.
ORCID-Profile: Fernanda Visioli
Förderung
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
Zitieren
APA
Gonçalves, D. R., Botelho, L. M., Carrard, V. C., Martins, M. A. T., & Visioli, F. (2024). Amitriptyline effectiveness in burning mouth syndrome: An in‐depth case series analysis. Gerodontology, 41(4), 548-555. https://doi.org/10.1111/ger.12750
Vancouver
Gonçalves DR, Botelho LM, Carrard VC, Martins MAT, Visioli F. Amitriptyline effectiveness in burning mouth syndrome: An in‐depth case series analysis. Gerodontology. 2024;41(4):548-555. doi:10.1111/ger.12750
BibTeX
@article{Gonalves2024,
author = {Gonçalves, Douglas Rodrigues and Botelho, Leonardo Monteiro and Carrard, Vinícius Coelho and Martins, Marco Antônio Trevizani and Visioli, Fernanda},
title = {Amitriptyline effectiveness in burning mouth syndrome: An in‐depth case series analysis},
journal = {Gerodontology},
year = {2024},
volume = {41},
number = {4},
pages = {548--555},
doi = {10.1111/ger.12750}
}
EUVIMED